If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...

Second Quarter 2025 Results Key Financial Results Revenue: US$3.68b (up ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a ...

Two presentations discussed the significant care disruptions when there are copay assistance shortages, with patients ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD ...

An extension of a pivotal phase 3 trial shows that the functional and anatomic benefits of Eylea HD (aflibercept 8 milligram dose) have staying power in people with neovascular (wet) age-related ...

AbbVie ( ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for its ...

LONG BEACH, Calif. -- Outcomes in neovascular age-related macular degeneration (nAMD) failed to improve with the addition of ...